Janus Henderson Group PLC Cerevel Therapeutics Holdings, Inc. Transaction History
Janus Henderson Group PLC
- $182 Billion
- Q2 2024
A detailed history of Janus Henderson Group PLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 293,385 shares of CERE stock, worth $0. This represents 0.01% of its overall portfolio holdings.
Number of Shares
293,385
Previous 37,242
687.78%
Holding current value
$0
Previous $1.57 Million
662.13%
% of portfolio
0.01%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CERE
# of Institutions
269Shares Held
155MCall Options Held
2.19MPut Options Held
3.92M-
Bain Capital Investors LLC Boston, MA65.7MShares$065.37% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$012.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.54MShares$04.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.15MShares$00.01% of portfolio
-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...